Cargando...
Anti-tumor antibodies can drive therapeutic T cell responses
The classical view of therapeutic monoclonal antibodies against tumor associated antigens is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of...
Guardado en:
| Publicado en: | Trends Cancer |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5657573/ https://ncbi.nlm.nih.gov/pubmed/28867165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trecan.2017.07.001 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|